Compugen discovered protein showed Recurring Relapses in Multiple Sclerosis Animal Model eliminationCompugen Ltd. announced that administration of CGEN-15001 in an animal model of multiple sclerosis has been shown abolish completely spontaneous relapses. In addition, administration of this novel molecule was before the onset of the disease is a pronounced delay of onset of illness and a significant decrease in disease symptoms. These results, together with complementary results of previous studies strongly support a significant potential therapeutic utility for CGEN-15001 in the treatment of multiple sclerosis and other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and type 1 diabetes..
CGEN-15001 is a soluble recombinant fusion protein consisting of the extracellular region comprises one Compugen discovered family member referred B7/CD28 CGEN – 15001T. CGEN – 15001T, even the potential medical assistance programs – such as as the target for antibody therapeutics – has been developed through the use of Compugen ‘s LEADS platform and a proprietary algorithm to discover new members known protein families to predict. Patents filed for both CGEN-15001 and CGEN – 15001T. Continue reading “Such as rheumatoid arthritis.”